Making a commitment in advance to buy vaccines if and when they are developed would create incentives for industry to increase investment in research and development. New commercial investment would complement funding of research and development (R&D) by public and charitable bodies, accelerating the development of vital new vaccines for the developing world.
This report presents the proposal from theory to practice, by showing how a commitment can be consistent with ordinary legal and budgetary principles. A draft contract term sheet is included, highlighting the key elements of a credible guarantee.
This generation can leave an historic legacy. By creating arrangements that devote the same scientific effort to diseases of the poor as we put into diseases of the rich, we can make a lasting contribution to the defeat of poverty.
As the last paragraph indicates, the report focuses on diseases that affect poor countries disproportionately, where funding from private sources is often insufficient. Still, the same logic applies to bird flu: the more orders for vaccines/anti-viral drugs, the more money will go into their production/research.